title: Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes.
abstract: BACKGROUND
  The objective of the study was to assess the effect of atorvastatin on inflammation markers and low-density lipoprotein (LDL) subfractions.
  
  
  METHODS
  In a prospective, randomized, double-blind pilot study involving 28 adolescents with type 1 diabetes (T1D), lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, high-sensitivity C-reactive protein (hsCRP), and subfractions of LDL were measured at baseline, after 1 year and 2 years of treatment with atorvastatin (10 mg/day) vs. placebo.
  
  
  RESULTS
  For the atorvastatin group, we found posttreatment reductions of Lp-PLA2 activity (p<0.001), LDL cholesterol (p=0.001), non-small dense LDL cholesterol (p<0.001), total cholesterol (p<0.001), and apolipoprotein B (apo B) (p<0.001), whereas small dense LDL cholesterol and hsCRP did not change significantly.
  
  
  CONCLUSIONS
  In adolescents with T1D, long-term treatment with atorvastatin is safe and may reduce cardiovascular risk by significant decreases of Lp-PLA2 activity and LDL cholesterol.
authors.forename: Andreas
authors.initials: A
authors.lastname: Krebs
authors.forename: Juergen
authors.initials: J
authors.lastname: Doerfer
authors.forename: Alexandra
authors.initials: A
authors.lastname: Krause
authors.forename: Juergen
authors.initials: J
authors.lastname: Grulich-Henn
authors.forename: Martin
authors.initials: M
authors.lastname: Holder
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hecker
authors.forename: Kai
authors.initials: K
authors.lastname: Lichte
authors.forename: Arno
authors.initials: A
authors.lastname: Schmidt-Trucksaess
authors.forename: Karl
authors.initials: K
authors.lastname: Winkler
authors.forename: Karl Otfried
authors.initials: KO
authors.lastname: Schwab
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000378:metabolism*; D000293:Adolescent; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000069059:Atorvastatin / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis*; D002097:C-Reactive Protein / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D000924:Anticholesteremic Agents; D015415:Biomarkers; D008078:Cholesterol, LDL; D002097:C-Reactive Protein; D000069059:Atorvastatin; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase